Abstract
The role of an advanced glycation end product/receptor for advanced glycation end product (AGE/RAGE) system in the pathogenesis of coronary artery disease (CAD) is not fully understood. To clarify whether polymorphisms of the RAGE gene were related to CAD, we performed a case–control study in Chinese Han patients. The allele frequencies and genotype distribution combinations of the −429T/C, 1704G/T and G82S polymorphisms of the RAGE gene were compared in 200 cases of hypertension (HT), 155 cases of CAD combined with HT (CAD&HT), 175 cases of CAD and 170 control subjects. Polymerase chain reaction-restriction fragment length polymorphism was used for detection of genotypic variants. The S allele frequency of the G82S polymorphism was higher in the CAD (odds ratio (OR), 2.303, 95% confidence interval (CI) 1.553–3.416; P<0.001, Pcorr<0.003) and CAD&HT (OR, 1.842; 95% CI 1.219–2.785; P<0.003, Pcorr<0.009) groups when compared with the control group. However, the S allele frequency was not significantly different between the CAD and the CAD&HT patient groups (P=0.223), and no statistically significant difference of genotype or allele frequency distributions was observed in the HT group (P>0.05). Meanwhile, serum CRP was significantly associated with the G82S variant. Haplotype-based logistic regression analysis revealed that haplotype G-Ser-T (OR, 1.670; 95% CI, 1.017–2.740; P=0.043), compared with the reference haplotype T-Gly-T, was associated with an increased risk of CAD after adjusting for other risk factors. Further analysis limited to non-diabetic participants exhibited similar significant findings. The haplotype carrying the G82S variant of the RAGE gene was significantly associated with an increased risk of CAD, but not with HT patients. Moreover, a remarkable association of the G82S variant with serum CRP levels implied that the prevalence of RAGE 82S allelic variation might influence susceptibility to CAD by affecting vascular inflammation.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ramasamy, R., Vannucci, S. J., Yan, S. S. D., Herold, K., Yan, S. F. & Schmidt, A. M. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15, 16–28 (2005).
Hudson, B. I., Hofmann, M. A., Bucciarelli, L., Wendt, T., Moser, B., Lu, Y. et al. Glycation and diabetes: the RAGE connection. Curr. Sci. 83, 1515–1521 (2002).
Cipollone, F., Iezzi, A., Fazia, M., Zucchelli, M., Pini, B., Cuccurullo, C. et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108, 1070–1077 (2003).
Hudson, B. I. & Schmidt, A. M. RAGE: a novel target for drug intervention in diabetic vascular disease. Pharm. Res. 21, 1079–1086 (2004).
Laki, J., Kiszel, P., Vatay, A., Blaskó, B., Kovács, M., Körner, A. et al. The HLA 8.1 ancestral haplotype is strongly linked to the C allele of −429T>C promoter polymorphism of receptor of the advanced glycation endproduct (RAGE) gene. Haplotype-independent association of the −429C allele with high hemoglobin(A1C) levels in diabetic patients. Mol. Immunol. 44, 648–655 (2007).
Hofmann, M. A., Drury, S., Hudson, B. I., Gleason, M. R., Qu, W., Lu, Y. et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun. 3, 123–135 (2002).
Zhang, H. M., Chen, L. L., Wang, L., Liao, Y. F., Wu, Z. H., Ye, F. et al. Association of 1704G/T and G82S polymorphisms in the receptor for advanced glycation end products gene with diabetic retinopathy in Chinese population. J. Endocrinol. Invest. 32, 258–262 (2009).
Jang, Y., Kim, J. Y., Kang, S. M., Kim, J. S., Chae, J. S., Kim, O. Y. et al. Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabolism 56, 199–205 (2007).
Ridker, P. M., Buring, J. E., Cook, N. R. & Rifai, N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 107, 391–397 (2003).
Zhong, Y., Li, S. H., Liu, S. M., Szmitko, P. E., He, X. Q., Fedak, P. W. et al. C-reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells. Hypertension 48, 504–511 (2006).
Wang, C. H., Li, S. H., Weisel, R. D., Fedak, P. W., Dumont, A. S., Szmitko, P. et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 107, 1783–1790 (2003).
Xu, D. L., Liu, Y. L., Meng, S. R., Weng, C. H., Liu, Z. Q. & Liu, Y. L. Changes in serum concentration of the advanced glycosylation end-product N epsilon-(carboxymethyl) lysine in patients with coronary heart diseases. Chin. J. Geriatr. Cardiovasc. Cerebrovasc. Dis. 2, 161–163 (2000).
Zeng, P., Xu, D. L., Li, Z., Lai, W. Y. & Ren, H. Effects of advanced glycation end-products on cell cycle distribution and apoptosis in neonatal rat cardiac myocytes. J. First. Mil. Med. Univ. 23, 9–11 (2003).
Shao, Y. H., Xu, D. L., Zeng, P., Lai, W. Y., Ren, H. & Jiang, R. Y. Transient cytosolic free calcium changes in cultured neonatal rat cardiac myocytes in response to advanced glycation end-product treatment. J. First. Mil. Med. Univ. 25, 274–276 (2005).
Kim, W., Hudson, B. I., Moser, B., Guo, J., Rong, L. L., Lu, Y. et al. Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis. Ann. NY Acad. Sci. 1043, 553–561 (2005).
Osawa, M., Yamamoto, Y., Munesue, S., Murakami, N., Sakurai, S., Watanabe, T. et al. De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts. Biochim. Biophys. Acta 1770, 1468–1474 (2007).
Chen, J. F., Huang, L., Song, M. B., Yu, S. Y., Gao, P. & Jing, J. C-reactive protein upregulates receptor for advanced glycation end products expression and alters antioxidant defenses in rat endothelial progenitor cells. J. Cardiovasc. Pharmacol. 53, 359–367 (2009).
Mahajan, N., Bahl, A. & Dhawan, V. C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. Int. J. Cardiol. 11733, 1–7 (2009).
Kankova, K., Záhejsky, J., Marova, I., Muzík, J., Kuhrová, V., Blazková, M. et al. Polymorphisms in the RAGE gene influence susceptibility to diabetes-associated microvascular dermatoses in NIDDM. J. Diabetes Comp. 15, 185–192 (2001).
Vasku, V., Kankova, K., Vasku, A., Muzík, J., Izakovicová, H. L., Semrádová, V. et al. Gene polymorphisms (G82S, 1704G/T, 2184A/G and 2245G/A) of the receptor of advanced glycation end products (RAGE) in plaque psoriasis. Arch. Dermatol. Res. 294, 127–130 (2002).
Hofmann, M. A., Yang, Q., Harja, E., Kedia, P., Gregersen, P. K., Cupples, L. A. et al. The RAGE Gly82Ser polymorphism is not associated with cardiovascular disease in the Framingham offspring study. Atherosclerosis 82, 301–305 (2005).
Yoon, S. J., Park, S., Shim, C. Y., Park, C. M., Ko, Y. G., Choi, D. et al. Association of RAGE gene polymorphisms with coronary artery disease in the Korean population. Coron. Artery Dis. 18, 1–8 (2007).
Kaplan, J. B. & Bennett, T. Use of race and ethnicity in biomedical publication. JAMA 289, 2709–2716 (2003).
Zee, R. Y., Romero, J. R., Gould, J. L., Ricupero, D. A. & Ridker, P. M. Polymorphisms in the advanced glycosylation end product-specific receptor gene and risk of incident myocardial infarction or ischemic stroke. Stroke 37, 1686–1690 (2006).
Yoshioka, K., Yoshida, T., Takakura, Y., Umekawa, T., Kogure, A., Toda, H. et al. Relation between polymorphisms G1704T and G82S of RAGE gene and diabetic retinopathy in Japanese type 2 diabetic patients. Intern. Med. 44, 417–421 (2005).
Xu, J. X., Xu, B. L., Yang, M. G. & Liu, S. Q. −429T/C and −374T/A polymorphisms of RAGE gene promoter are not associated with diabetic retinopathy in Chinese patients with type 2 diabetes. Diabet. Care 26, 2696–2697 (2003).
Acknowledgements
We thank the DNA donors and the supporting medical staff for making this study possible, and also thank Y Eugene Chen (Associate Professor of Internal Medicine, Cardiovascular Center University of Michigan Medical Center) for revising this article. This work was supported by the Guangdong Natural Science Foundation of the People's Republic of China (10717) and by grants from the National Key Basic Research Development Plan of People's Republic of China (G200056905).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Gao, J., Shao, Y., Lai, W. et al. Association of polymorphisms in the RAGE gene with serum CRP levels and coronary artery disease in the Chinese Han population. J Hum Genet 55, 668–675 (2010). https://doi.org/10.1038/jhg.2010.85
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/jhg.2010.85
Keywords
This article is cited by
-
Relationship between RAGE gene polymorphisms and cardiovascular disease prognosis in the Chinese Han population
Molecular Genetics and Genomics (2017)
-
Association between the receptor for advanced glycation end products gene polymorphisms and coronary artery disease
Molecular Biology Reports (2013)
